aTyr Pharma (NASDAQ:ATYR) Announces Quarterly Earnings Results

aTyr Pharma (NASDAQ:ATYR) issued its quarterly earnings data on Friday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05, FiscalAI reports.

aTyr Pharma Stock Down 10.0%

Shares of NASDAQ ATYR traded down $0.06 during midday trading on Friday, hitting $0.50. The company had a trading volume of 3,510,665 shares, compared to its average volume of 1,909,190. aTyr Pharma has a twelve month low of $0.40 and a twelve month high of $7.29. The business has a 50-day simple moving average of $0.82 and a two-hundred day simple moving average of $0.81. The firm has a market capitalization of $49.42 million, a price-to-earnings ratio of -0.64 and a beta of 0.66.

Hedge Funds Weigh In On aTyr Pharma

Institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System acquired a new position in shares of aTyr Pharma in the second quarter worth $28,000. ADAR1 Capital Management LLC raised its holdings in shares of aTyr Pharma by 35.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after acquiring an additional 13,385 shares during the last quarter. Legal & General Group Plc acquired a new position in shares of aTyr Pharma in the second quarter worth $49,000. Virtu Financial LLC acquired a new position in shares of aTyr Pharma in the fourth quarter worth $62,000. Finally, Prudential Financial Inc. acquired a new position in shares of aTyr Pharma in the second quarter valued at approximately $63,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ATYR shares. Jefferies Financial Group reissued a “buy” rating on shares of aTyr Pharma in a research report on Friday, March 6th. Wall Street Zen downgraded shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, aTyr Pharma currently has an average rating of “Hold” and an average price target of $25.67.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.